On Tuesday, Philip Morris International Inc. (NYSE:PM)’s shares declined -0.29% to $82.95.
Rothmans, Benson & Hedges Inc., the Canadian partner of Philip Morris International Inc. (PM), will appeal the judgment of a trial court in Québec that found in favor of plaintiffs in two class action lawsuits.
Philip Morris International Inc. is not a party to the cases and is not liable for any portion of this judgment.
Philip Morris International Inc. and its associates have been involved in tobacco litigation since 1995 and have been overwhelmingly successful in defending themselves,” said Firestone. “Courts around the world have concluded that smokers are well aware of the dangers of smoking and are not entitled to money damages in light of these well-known dangers
Philip Morris International Inc., through its auxiliaries, manufactures and sells cigarettes, other tobacco products, and other nicotine-containing products. Its portfolio of brands comprise Marlboro, Merit, Parliament, Virginia Slims, L&M, Chesterfield, Bond Street, Lark, Muratti, Next, Philip Morris, and Red & White.
Eli Lilly and Co (NYSE:LLY)’s shares dropped -1.33% to $77.95.
Eli Lilly and Co (LLY) will take part in the White House Forum on Antibiotic Stewardship where Elanco President Jeff Simmons will take part in a panel talk aboution. Conpresently, Simmons is unveiling the company’s multi-faceted approach to combat the growing concern about antibiotic resistance. A summary of Simmons’ remarks follows:
In the next few decades, demand for animal protein will climb 60 percent[1] as population enhances and the global middle class expands by three billion people[2]. These numbers are important, because we’re already overusing the Earth’s resources, consuming about 1.5 times the natural resources we should use in a year[3]. Delivering safe, sufficient, affordable protein to feed the growing population has never been at greater risk.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
At the end of Tuesday’s trade, Pandora Media Inc (NYSE:P)‘s shares dipped -0.43% to $18.34.
Pandora Media Inc (P) the leading internet radio service, has partnered with Mumford & Sons and Glassnote Records to livestream the band’s sold out Merriweather Post Pavilion show on Wednesday, June 10 at 9 PM EST.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
Regulus Therapeutics Inc (NASDAQ:RGLS), ended its Tuesday’s trading session with -16.33% loss, and closed at $11.53.
Regulus Therapeutics Inc (RGLS) declared that Kleanthis G. Xanthopoulos, Ph.D. has resigned as President and Chief Executive Officer and as a member of Regulus’ Board of Directors, effective recently, to pursue investment opportunities in the biotechnology industry. Paul Grint, M.D., who formerly served as Chief Medical Officer of Regulus, has been designated as President and Chief Executive Officer and as a member of Regulus’ Board of Directors effective recently. In addition, Neil W. Gibson, Ph.D., who has served as Chief Scientific Officer, will continue through June 30, 2015 at the company as President’s Fellow to assist Dr. Grint in assembling a new leadership team.
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
